ABSTRACT-The effects of NG-nitro-L-arginine methyl ester (L-NAME), the nitric oxide (NO) syn thase inhibitor, on gastric HC03 secretion were examined in anesthetized rats. Intravenous adminis tration of L-NAME (1, 2.5, 5 mg/kg) increased HC03 secretion in a dose-related manner. This effect of L-NAME was mimicked by NG-mono-methyl-L-arginine (50 mg/kg, i.v.) and was antagonized signifi cantly by concurrent administration of L-arginine but not D-arginine (200 mg/kg, i.v.). These results in dicate that gastric HC03 secretion is stimulated by inhibition of NO biosynthesis.
Nitric oxide (NO), synthesized from the semi-essen tial amino acid L-arginine by NO synthase in the vascu lar endothelium is now established to mediate various biological actions under physiological conditions (1) . Recent studies have shown that NO also plays an im portant role in the modulation of the gastric mucosal integrity by interacting with other protective mediators (2, 3) . Regulation of gastric mucosal blood flow is con sidered to be the major mechanism responsible for the mucosal protective action of NO (2, 4) , yet the influ ences of the inhibition of NO biosynthesis on other de fensive factors such as HC03 secretion has not been studied. In the present study, we thus examined the effects of the NO synthase inhibitor on HC03 secre tion in the rat stomach using NG-nitro-L-arginine as the methyl ester (L-NAME) and characterized these effects in relation to endogenous NO.
Male Sprague Dawley rats (230 250 g), kept in indi vidual cages with raised mesh bottoms, were deprived of food but allowed free access to tap water for 18 hr before the experiments. The animals were anesthetized with urethane (1.25 g/kg, i.p.; Tokyo Kasei); and then the stomach was exposed, mounted on a chamber (ex posed area: 3.14 cm2), and perfused with saline that was gassed with 100% 02. HC03 secretion was deter mined at pH 7.0 by continuous titration of the perfusate with 10 mM HCl under acid inhibition by omeprazole (60 mg/kg, i.p.). In some cases, the stomach was per fused with acidified saline (pH 4.5) at the rate of 1 ml/min, and the pH of the perfusate and transmucosal potential difference (PD) were monitored simultaneous ly with arterial blood pressure (BP). The pH was meas ured by a flow type glass electrode (Horiba, Model 6901-25T), while PD was determined by using two agar bridges, one positioned in the chamber and the other in the abdominal cavity (5) . BP was monitored via the femoral artery by a pressure transducer and amplifier system (Nihon Kohden). NG-nitro-L-arginine methyl ester (L-NAME: Sigma), NG-monomethyl-L-arginine (L-NMMA: Sigma) and prostaglandin E2 (PGE2, Funa koshi) were given i.v. after basal secretion had stabi lized. In some cases, L or D-arginine (Wako) was given i.v. 5 min before administration of L-NAME. Data are presented as the mean ± S.E. from 5-6 rats. Statistical analyses were performed by the two-tailed Dunnett's multiple comparison test, and values of P < 0.05 were regarded to indicate a significant difference.
In the animals pretreated with omeprazole, the gas tric mucosa mounted on a chamber and perfused with acidified saline (pH 4.5) generated a PD of -40 -45 mV (mucosa negative) , secreted alkali to keep the luminal pH at 4.8-5.2, and BP was maintained around 90 -100 mmHg. Intravenous administration of L-NAME at 5 mg/kg produced a marked increase of pH with a slight decrease in PD and persistent rise in BP (Fig. 1) . Titration of the perfusate with 10 mM HCI at pH 7.0 revealed the production of about 0.2-0.4 ,u Eq of HCO3 every 5 min, and this rate was well maintained during the 90 min-test period. Administra tion of L-NAME (1, 2.5 and 5 mg/kg) increased gastric HCO3 output significantly in a dose-related manner, and this secretion at 5 mg/kg reached maximal levels (0.85 ± 0.16 ,u Eq/5 min) of 4 times greater than the basal values (0.23 ± 0.03,uEq/5 min) and remained elevated for 1 hr; AHC03 output was 5.6 ± 1.0 ,u Eq/hr, which is almost equivalent to that (4.8 ± 1.0 ,uEq/hr) induced by PGE2 (0.3 mg/kg) (Fig. 2, A and B). Gastric HCO3 secretion was also stimulated sig nificantly by another NO synthase inhibitor, L-NMMA (50 mg/kg), ,AHC03 output being 2.4 ± 0.7 ,uEq/hr. On the other hand, the stimulatory effect of L-NAME (5 mg/kg) on gastric HC03 secretion was significantly antagonized by pretreatment with L-arginine (200 mg/kg, i.v.) at the dose which partially mitigated the rise in BP seen after administration of L-NAME (%increase in BP at 5 min-post treatment: 41.7 ± 2.6% vs. 26.4 ± 4.6%, P < 0.05). In the rats pretreated with L-arginine, the AHC03 output induced by L-NAME was 1.3 ± 0.6 pEq/hr, which is about 23.2% of the dHC03_ output obtained in control animals given L NAME alone. D-Arginine did not affect the increased HCO3 response to L-NAME. plus L-NAME, ED-arginine plus L NAME). [B] : Values indicate the net HC03 output obtained for 1 hr after the treatments and represent the means ± S.E. from 5 6 rats. *Statistically significant difference from the group given L NAME alone, at P < 0.05.
The present study showed that gastric HCO3 secre tion was significantly stimulated by the NO synthase in hibitor L-NAME in the anesthetized rats. It is unlikely that the increase of luminal alkalinization by L-NAME is brought about by an inhibition of acid secretion, be cause in this study, HCO3 secretion was measured in the animals pretreated with omeprazole, by which acid secretion had been completely blocked. On the other hand, the effect of L-NAME on HCO3 secretion may appear through inhibition of NO biosynthesis but is not attributable to the non-specific action of this agent. This contention is supported by the following findings:
(a) another NO synthase inhibitor, L-NMMA, in creased gastric HCO3 secretion similar to L-NAME and (b) the effect of L-NAME was significantly antago nized by concurrent administration of L-arginine but not by D-arginine. In a preliminary study, we also found that L-NAME increased HC03 secretion in the rat duodenum and that this effect was significantly antago nized by L-arginine or the exogenous NO donner nitroprusside (unpublished data, K. Takeuchi et al.).
These results suggest that NO may be involved as the endogenous inhibitor in the regulation of HC03 secre tion. The increased HCO3 responses induced by L NAME were accompanied by the decrease in gastric PD and the persistent rise in systemic BP. Kubes and Granger (6) reported that inhibition by L-NAME of NO production by vascular endothelium leads to a re versible rise in microvascular protein efflux in the cat ileum. Although the mechanism by which the inhibition of NO biosynthesis increased HCO3 secretion remains unknown, it might be assumed that these phenomena are causally-related to the increased HC03 responses to L-NAME. Certainly, since other vasopressor agents such as norepinephrine and vasopressin are known to inhibit HC03 secretion (7, 8) , it is unlikely that the elevation of BP simply leads to an increase of HC03 secretion.
In general, HC03 secretion is considered as one of the defensive factors in the stomach as well as in the duodenum (9, 10) . The present results seem to be in consistent with the protective role of NO in the gastric mucosa. The HCO3 secretion in the stomach is known to increase in response to vagal excitation or agents that stimulate acid secretion (11, 12) . Barrachina et al. (13) recently reported that L-NAME significantly reversed the antisecretory effect of endotoxin on distention-stimulated acid output and suggested the in volvement of NO in the regulation of acid secretion. If HC03 secretion is physiologically important as an acid-neutralizing factor, it would be understandable that NO suppresses the "protective HCO3-" as well as the "aggressive H+" secretions .
The present study showed for the first time that the administration of L-NAME stimulates gastric HCO3 secretion in anesthetized rats, although the mechanisms responsible for this phenomenon have not been fully evaluated yet. Further studies to elucidate the role of NO in the regulation of HC03 secretion are war ranted.
